Shares of Alivus Life Sciences Ltd. surged 5.23% to close at ₹1,181.40 on January 23, following the release of the company’s Q3 FY25 financial results, which highlighted strong growth in key financial metrics.
Key Financial Highlights (Q3 FY25 vs Q3 FY24):
- Revenue from Operations: ₹641.84 crore, a 12% YoY increase from ₹572.80 crore.
- Total Income: ₹652.3 crore, up 13.6% YoY from ₹574.50 crore.
- Profit Before Tax (PBT): ₹185.14 crore, reflecting 15% YoY growth from ₹160.68 crore.
- Net Profit (PAT): ₹136.96 crore, a notable 15% rise YoY from ₹118.77 crore.
Operational Highlights:
- The company achieved improved operational efficiencies and strategic cost management.
- Total expenses grew proportionally to revenue, with material costs increasing to ₹287.61 crore compared to ₹243.13 crore in Q3 FY24.
Nine-Month Performance (9M FY25 vs 9M FY24):
- Revenue: ₹1,761.82 crore, marginally higher than ₹1,755.53 crore.
- Net Profit: ₹343.76 crore, reflecting a 6% YoY decline due to increased tax expenses.
The strong quarterly performance and strategic focus on cost efficiencies have boosted investor confidence, driving the stock’s gains.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
